Clinical trials
Relapsed or Refractory B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06746480RecruitingPhase 2
Study of VG161 for advanced bile duct cancer
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07539727Recruiting
Intestinal ultrasound to predict Crohn's disease flare-ups
This study tests whether a special ultrasound of the intestines can predict when Crohn's disease will flare up again in patients whose disease is currently well-controlled. If successful, doctors could catch flare-ups earlier and adjust treatment before symptoms worsen.
Guangzhou, GuangdongAges 18–70 - NCT07535645RecruitingPhase 1/Phase 2
Baricitinib for Low Platelet Counts After Bone Marrow Transplant
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Beijing, Beijing MunicipalityAges 18–70 - NCT06749990Recruiting
Alcohol relapse risk after liver transplant
This study looks at why some people with alcohol-related liver disease start drinking again after a liver transplant. It aims to find factors that increase or decrease that risk.
BolognaAges 18 years+ - NCT07532161Recruiting
Fibrin and Laser Treatment for Gummy Smile Surgery
This study compares two treatment approaches—liquid fibrin (a clotting substance) and soft laser therapy—to help healing and prevent relapse after surgery to reduce a gummy smile caused by an overactive upper lip. The goal is to find which method works better for long-term results.
Damascus, Rif-dimashq GovernorateAges 18–50 - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07517185RecruitingPhase 2
Early aggressive treatment for relapsing multiple sclerosis
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
FalunAges 18–50 - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07510607RecruitingPhase 2
Metabolic imaging study for multiple sclerosis
This study tests a new imaging method using a special substance called hyperpolarized 13C pyruvate to see how it can help understand multiple sclerosis. You may join if you have relapsing-remitting MS, have not used disease-modifying treatments in the past two years, and are planning to start anti-CD20 therapy.
San Francisco, CaliforniaAges 18 years+ - NCT07509749RecruitingPhase 2
New treatments for severe acute GVHD after stem cell transplant
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
BeijingAges 14 years+ - NCT06760260RecruitingEarly Phase 1
FLT3-targeted CAR-T cell therapy for relapsed AML
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
Suzhou, JiangsuAges 18–70 - NCT06657690RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after immunotherapy
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
Zhuhai, GuangzhouAges 18–70 - NCT06783790RecruitingPhase 2
Avapritinib combo for relapsed AML after transplant
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
TianjinAges 18 years+ - NCT06223880RecruitingPhase 4
AXS-05 vs Bupropion to prevent depression relapse
This study tests whether a new drug called AXS-05 can prevent depression from coming back, compared to an older drug called bupropion. If you have major depression and are at risk of relapse, this trial may help you stay well.
Bellflower, CaliforniaAges 18–65 - NCT07471789RecruitingPhase 1/Phase 2
CART84 therapy for AML and T-ALL leukemia
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Barcelona, BarcelonaAges 18 years+ - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT04857164RecruitingPhase 2
Pembrolizumab plus chemotherapy for recurrent or metastatic throat cancer
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07448324RecruitingPhase 2
Orelabrutinib plus rituximab with or without lenalidomide for untreated MZL
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
Nanjing, JiangsuAges 18 years+ - NCT07447635Recruiting
Testing a program to help cancer survivors quit smoking and reduce drinking
This study tests a program (MBI) to help cancer survivors quit smoking and cut back on alcohol. It's designed for people who want to make these changes in the next 30 days.
Tampa, FloridaAges 18 years+ - NCT07439211RecruitingPhase 1
Testing a new drug combo for acute myeloid leukemia
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
Boston, MassachusettsAges 18–90 - NCT07426991Recruiting
Multiple sclerosis, thinking, sleep, and tiredness study
This study looks at how multiple sclerosis (MS) affects your thinking, sleep, and tiredness. It compares people with MS who have at least mild fatigue to people without MS who also have sleep problems, to understand these issues better.
DüsseldorfAges 18–79 - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT07403630Recruiting
Tumor chemogenomic profiler for cancer patients of all ages
This trial uses a new testing platform to analyze the genes and proteins in your tumor, aiming to find the most effective treatments for people with cancer that has come back, is not responding to treatment, or has spread. It is designed for both children and adults with any type of blood cancer or solid tumor.
Palermo, PalermoAges 1 year+ - NCT07404332RecruitingPhase 1
Combination therapy for tumors resistant to immunotherapy
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
Iowa City, IowaAges 18–99
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell lymphoma?
- Yes. Clin2 currently lists 1,718 recruiting relapsed or refractory b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.